Claims
- 1. The O-acetyl derivative of antibiotic EM-49 and acid salts thereof, the hydrochloride having the infrared absorption spectrum as in FIG. 5, the NMR spectrum as in FIG. 6, the approximate elemental analysis of anhydrous material: C, 51.10; H, 8.00; N, 14.90; Cl, 11.60; the approximate empirical formula C.sub.52 H.sub.97 N.sub.13 O.sub.11 Cl.sub.4 and an approximate molecular weight of 1222.
- 2. The hydrochloride of the product of claim 1.
- 3. The tetra(benzyloxycarbonyl) derivative of antibiotic EM-49 having the infrared absorption as in FIG. 1, the NMR spectrum as in FIG. 2, the approximate elemental analysis of anhydrous material: C, 61.27; H, 6.69; N, 11.37; the approximate empirical formula C.sub.82 H.sub.115 N.sub.13 O.sub.18 and an approximate molecular weight of 1571.
- 4. The tetra(benzyloxycarbonyl)-O-acetyl derivative of antibiotic EM-49, having the infrared absorption spectrum as in FIG. 3, the NMR spectrum as in FIG. 4, the approximate elemental analysis of anhydrous material: C, 61.63; H, 7.25; N, 11.68; the approximate empirical formula C.sub.84 H.sub.117 N.sub.13 O.sub.19 and an approximate molecular weight of 1613, and acid salts thereof.
- 5. The O-butyryl derivative of antibiotic EM-49 and acid salts thereof, the hydrochloride having the infrared absorption spectrum as in FIG. 7, the approximate elemental analysis of anhydrous material, as the hydrochloride: C, 52.45; N, 14.40; Cl.sup.-, 11.17; the approximate empirical formula C.sub.54 H.sub.101 N.sub.13 O.sub.11 Cl.sub.4 and an approximate molecular weight of 1250.
- 6. The O-hexanoyl derivative of antibiotic EM-49, and acid salts thereof, having the infrared absorption spectrum as in FIG. 9, the approximate elemental analysis of anhydrous material: C, 59.83; N, 15.76; the approximate empirical formula C.sub.56 H.sub.101 N.sub.13 O.sub.11 and an approximate molecular weight of 1132.
- 7. The O-octanoyl derivative of antibiotic EM-49, and acid salts thereof, the hydrochloride having the infrared spectrum as in FIG. 12, the approximate elemental analysis: C, 51.97; H, 8.37; N, 12.96; Cl.sup.-, 10.12; the approximate empirical formula C.sub.58 H.sub.109 N.sub.13 O.sub.11 Cl.sub.4 and an approximate molecular weight of 1306.
- 8. A compound of the formula ##EQU3## wherein Dab is 2,4-diaminobutyric acid, Y is L-leucine or L-phenylalanine; X is ##EQU4## R.sup.1 is C.sub.7 H.sub.15 or C.sub.8 H.sub.17 ; and R.sup.2 is lower alkanoyl, and acid salts thereof.
- 9. A compound as in claim 8 wherein Y is L-leucine.
- 10. A compound as in claim 8 wherein Y is L-phenylalanine.
- 11. A compound as in claim 8 wherein R.sup.2 is acetyl.
- 12. A compound as in claim 8 wherein R.sup.2 is butyryl.
- 13. A compound as in claim 8 wherein R.sup.2 is hexanoyl.
- 14. A compound as in claim 8 wherein R.sup.2 is octanoyl.
- 15. Acid addition salt of a compound as in claim 13.
- 16. Hydrochloride of a compound as in claim 13.
- 17. A compound as in claim 9 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is acetyl.
- 18. A compound as in claim 9 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is acetyl.
- 19. A compound as in claim 9 wherein R is C.sub.7 H.sub.15 and R.sup.2 is butyryl.
- 20. A compound as in claim 9 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is butyryl.
- 21. A compound as in claim 9 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is hexanoyl.
- 22. A compound as in claim 9 wherein R.sup.1 C.sub.8 H.sub.17 and R.sup.2 is hexanoyl.
- 23. A compound as in claim 9 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is octanoyl.
- 24. A compound as in claim 9 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is octanoyl.
- 25. A compound as in claim 10 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is acetyl.
- 26. A compound as in claim 10 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is acetyl.
- 27. A compound as in claim 10 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is butyryl.
- 28. A compound as in claim 10 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is butyryl.
- 29. A compound as in claim 10 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is hexanoyl.
- 30. A compound as in claim 10 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is hexanoyl.
- 31. A compound as in claim 10 wherein R.sup.1 is C.sub.7 H.sub.15 and R.sup.2 is octanoyl.
- 32. A compound as in claim 10 wherein R.sup.1 is C.sub.8 H.sub.17 and R.sup.2 is octanoyl.
- 33. A compound as in claim 10 wherein X is 2-hexanoyloxy-8-methyldecanoyl.
Parent Case Info
This application is a continuation-in-part of application Ser. No. 357,735, filed May 7, 1973, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3753970 |
Bouchaudon et al. |
Aug 1973 |
|
3817973 |
Bouchaudon et al. |
Jun 1974 |
|
Non-Patent Literature Citations (1)
Entry |
Miller, The Pfizer Handbook of Microbial Metabolites, McGraw-Hill Book Co., Inc., N.Y., N.Y., 1961, p. 371. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
357735 |
May 1973 |
|